Long-acting risperidone improves negative symptoms in stable psychotic patients
- 28 February 2008
- journal article
- other
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 22 (3), 254-261
- https://doi.org/10.1177/0269881107082119
Abstract
The aim of this paper was to evaluate the efficacy of risperidone long-acting injectable (RLAI) for reducing negative symptoms of schizophrenia in patients with predominantly negative symptoms at baseline. A subanalysis was performed on data from the 6-month, open-label Switch to Risperidone Microspheres trial. Patients with Positive and Negative Syndrome Scale (PANSS) negative subscale score ≥21, which was higher than their PANSS positive subscale score, were included in this subanalysis. Improvement in negative symptoms was measured by assessing change in the PANSS negative subscale and a negative factor score. Additional outcome variables included measures in general functioning, quality of life and patient satisfaction. A total of 842 patients were eligible for inclusion in this subanalysis. Six months of treatment was completed by 631 (74.9%) patients. Forty-three (5.1%) patients discontinued treatment due to an adverse event. Negative symptoms were significantly reduced by 6.1 ± 6.3 points for the PANSS negative score and 6.1 ± 6.4 points for the negative factor score ( P < 0.0001 for both). Significant improvements were also noted for total PANSS and other PANSS subscale scores, general functioning, quality of life and patient satisfaction ( P < 0.0001). The most common treatment-emergent adverse events (>5%) were: anxiety (6.8% of patients), exacerbation of disease (6.2%) and insomnia (5.7%). Overall, RLAI was well tolerated and associated with significant reductions in movement disorder severity. The treatment resulted in a significant improvement in negative symptom severity and was well tolerated in patients with predominantly negative symptoms, who switched from a stable antipsychotic regimen.This publication has 28 references indexed in Scilit:
- Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disordersPsychopharmacology, 2006
- Nocturnal hormone profiles in patients with schizophrenia treated with olanzapinePsychoneuroendocrinology, 2006
- Treatment of Schizophrenia Negative Symptoms: Future ProspectsSchizophrenia Bulletin, 2006
- The NIMH-MATRICS Consensus Statement on Negative SymptomsSchizophrenia Bulletin, 2006
- Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychoticsPrimary Care and Community Psychiatry, 2005
- Manual for the Extrapyramidal Symptom Rating Scale (ESRS)Schizophrenia Research, 2005
- Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialInternational Journal of Neuropsychopharmacology, 2005
- Treatment of Schizophrenia With Long-Acting Injectable RisperidonePublished by Physicians Postgraduate Press, Inc ,2003
- Structure and Course of Positive and Negative Symptoms in SchizophreniaArchives of General Psychiatry, 1995
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987